Acelyrin (Acelyrin) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Acelyrin Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Acelyrin's Capital Expenditure for the three months ended in Mar. 2024 was $-0.06 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-82.77 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Acelyrin Capex-to-Operating-Income Historical Data

The historical data trend for Acelyrin's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acelyrin Capex-to-Operating-Income Chart

Acelyrin Annual Data

Trend

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Acelyrin Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Operating-Income	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Acelyrin's Capex-to-Operating-Income

For the Biotechnology subindustry, Acelyrin's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acelyrin's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acelyrin's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Acelyrin's Capex-to-Operating-Income falls into.

Acelyrin Capex-to-Operating-Income Calculation

Acelyrin's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-12.294)	/	-422.064
	=	N/A

Acelyrin's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.055)	/	-82.774
	=	N/A

Acelyrin (NAS:SLRN) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Acelyrin Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Acelyrin's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Acelyrin (Acelyrin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acelyrin Inc (NAS:SLRN) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

4149 Liberty Canyon Road, Agoura Hills, CA, USA, 91301

Website

https://www.acelyrin.com

Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates.

Executives

Shao-lee Lin	director, officer: Chief Executive Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Gil M Labrucherie	officer: Interim CFO	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Beth C Seidenberg	director, 10 percent owner
Henry O Gosebruch	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Mardi Dier	officer: CFO and CBO	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Mina Kim	officer: Chief Legal & Admin. Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Ronald Oyston	officer: Chief People Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Paul Peloso	officer: Chief Medical Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Daniel J. Becker	director	C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Westlake Biopartners Fund Ii, L.p.	10 percent owner	3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361
Ayurmaya Capital Management Company, Lp	director, 10 percent owner, other: See Remarks	1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Sean E Harper	10 percent owner	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Melanie Gloria	officer: Chief Operating Officer	C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Westlake Biopartners Gp Ii, Llc	10 percent owner	3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361